Navigation Links
HealthEdge(R) Announces Systems Integration Partnership With maxIT Healthcare
Date:4/2/2009

Leading healthcare consulting firm to implement the revolutionary new HealthRules(R) product suite

BURLINGTON, Mass., April 2 /PRNewswire/ -- HealthEdge, provider of the only modern enterprise-class software platform for healthcare payors, today announced that it has partnered with Indiana-based maxIT Healthcare to implement the patented, award-winning HealthRules software at healthcare payor organizations.

"We are excited to announce our new partnership with maxIT Healthcare," said Rob Gillette, CEO of HealthEdge. "Given the proven industry veterans on their team, we are confident that they thoroughly understand the challenges that the market is facing, and we believe that our customers will benefit significantly from their knowledge and expertise. We are looking forward to working with them on a number of upcoming client engagements."

"By leveraging both the power of the HealthRules product suite and maxIT Healthcare's proven industry experience, we are able to offer significant value to healthcare payors of all types and sizes," said Bruce Oliver, maxIT Healthcare's Payer Practice Director. "Using this new technology, payors will now be able to quickly and easily offer new products, improve their margins, and enhance customer service and operational efficiency. We are delighted to be working together with HealthEdge to bring these important new capabilities to the healthcare market."

maxIT Healthcare's certified HealthRules deployment engineers will provide a full range of implementation and integration services to HealthEdge clients, including system installation, configuration, training, data conversion, maintenance and project management.

About HealthEdge

HealthEdge provides the only modern, enterprise-class software platform for healthcare payors. Using the patented HealthRules(R) software suite, health plans, health insurance companies and o
'/>"/>

SOURCE HealthEdge
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit
2. Mississippi Administrative Services Chooses the HealthRules(R) Product Suite from HealthEdge(R) to Address Next-Generation Business Needs
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...fe remains unclear, researchers say , , ... suggests that enzyme replacement therapy can make...bry disease, a rare illness that affects the kidne..., linked to the lack of an enzyme that helps metab...ecause it boosts the risk for a stroke, heart atta...
(Date:12/2/2009)...Y., Dec. 2 Researchers ...in blood cancer research at the annual American So...s December 4-8, 2009. ,, Throughout the ASH co...) experts, including Chief Medical Officer Barton ...nt Services Hildy Dillon, and Vice President, Rese...
(Date:12/2/2009)...y federal government ends nine months of obstructi...RNewswire-USNewswire/ -- More than 2,300 healthcar...ilities across Southern California will soon vote ...Healthcare Workers (NUHW). ,, A majority of the... but SEIU delayed the election by filing frivolous...
(Date:12/2/2009)...al congress of the European Association of Echocar...an Society of Cardiology, where techniques of non-... New case reports will be presented at this year,...the role of this new technology. , Now, with su...likely that non-invasive imaging will gain more im...
(Date:12/2/2009)...ional Race Series to increase awareness of prostat... importance of early detection , ..., women, families, friends and neighbors – a...ipate in the Rudolph Ramble 5K. The Rudolph Rambl... which was launched by the Prostate Conditions Ed...
Breaking Medicine News(10 mins):Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2Health News:Media alert: EUROECHO 2009 2Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4
... announced today that it has submitted a supplemen...and Drug Administration (FDA) for VYVANSE(TM) (lis...ention Deficit Hyperactivity Disorder (ADHD) in ad... Matthew Emmens, Shire Chief Executive Officer. "W...
...he abattoir, especially because it is afflicted wi... the mad cow disease that took a heavy toll of th...year-old Freisian bull to the slaughterhouse is bu... the Wales health authorities. The bull is sacred...
...an alert following a malaria epidemic that has cla...people. "Doctors and paramedics have been ...uding mobile units, fanning out to vulnerable area...the mosquito-borne disease. "Between Janua...
...the war veterans who have come back after combat i...to the exposure to chemicals and other harmful sub...regions that are closely linked to learning and me...an Academy of Neurology's 59th Annual Meeting in B...
...evere chest pain today are much less likely to die...r counterparts even a few years ago, according to... time that a study has shown a significant drop in...t hospitals increased their use of certain drugs, ...
...iled to improve symptoms of moderate to severe chr... large, multi-center trial. The results o... trial of infliximab were published in the first i...ial commenting on the research, the failure of the...
Other Medicine News:Health News:VYVANSE(TM) Drug for the Treatment of ADHD in Adults 2Health News:Shambu With Bovine TB Being Prevented from Slaughter 2Health News:Malaria Claims 25 Lives in Assam 2Health News:Gulf War Veterans Exhibit Memory Impairment 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2
(Date:12/2/2009)...sreal, December 2 Cardio...g developer of advanced,cardiovascular surgery tec...of Directors approved a one-for-three forward stoc...to Cardio Vascular Medical Device shareholders. ,...he estimated date the stock,split will be payable ...
(Date:12/2/2009)...., Dec. 2 Roche (SIX: RO...ed States Food & Drug Administration (FDA) app...nucleic acid test, to screen source plasma in pool...test, called the cobas® TaqScreen MPX Test fo...e, in-vitro test for the simultaneous, direct dete...
(Date:12/2/2009)...VER, N.J., Dec. 2 Novartis announc...presentation on Tasigna® (nilotinib) 200 mg c...onstrate the strength of the company,s hematology ..., The new data, at the 51st American Society of He...light the company,s current therapies and investig...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Advance in bowel cancer test research 48298 1Discovery raises new doubts about dinosaur bird links 8763 1Discovery raises new doubts about dinosaur bird links 8763 2Discovery raises new doubts about dinosaur bird links 8763 3Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 1Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 2Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 3
... WIRE)--Apr 23, 2007 - Aeolus,Pharmaceuticals, Inc...by researchers at Loma Linda University Medical Ce...hyrin antioxidants, AEOL,10113, may play an import...y ionizing radiation., Radiation therapy is used a...py in the care and management of nearly all adult ...
...eight loss medication Xenical,(orlistat 120mg) sig...lar risk factors such as blood pressure, glycaemic... people with type,2 diabetes and hypertension, acc...an Congress on Obesity (ECO), Budapest,Hungary.(1...already established,for Xenical that demonstrates ...
Other Medicine Technology:Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 2Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6
Wire Driver, Cannulated
Micro Saggital Saw
SmartDriver
Large Power Battery/Electric Reciprocating Saw
Medicine Products: